Iniguez AB, Stolte B, Wang EJ, et al. EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. Cancer Cell. 2018;33(2):202-216.e6. doi:10.1016/j.ccell.2017.12.009PubMedGoogle ScholarDOI
Boulay G, Volorio A, Iyer S, et al. Epigenome editing of microsatellite repeats defines tumor-specific enhancer functions and dependencies. Genes Dev. 2018;32(15-16):1008-1019. doi:10.1101/gad.315192.118PubMedGoogle ScholarDOI
Boulay G, Sandoval GJ, Riggi N, et al. Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain. Cell. 2017;171(1):163-178.e19. doi:10.1016/j.cell.2017.07.036PubMedGoogle ScholarDOI
Gorthi A, Romero JC, Loranc E, et al. EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. Nature. 2018;555(7696):387-391. doi:10.1038/nature25748PubMedGoogle ScholarDOI
Stegmaier K, Wong JS, Ross KN, et al. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med. 2007;4(4):e122. doi:10.1371/journal.pmed.0040122PubMedGoogle ScholarDOI
Smith R, Owen LA, Trem DJ, et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing’s sarcoma. Cancer Cell. 2006;9(5):405-16. doi:10.1016/j.ccr.2006.04.004PubMedGoogle ScholarDOI
Riggi N, Knoechel B, Gillespie SM, et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell. 2014;26(5):668-81. doi:10.1016/j.ccell.2014.10.004PubMedGoogle ScholarDOI